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Abstract : This study examined the effect of thiotriazinone impurity on the genera-
tion of insoluble microparticles （IMPs） associated with ceftriaxone-calcium salt 
precipitation in original （RocephinⓇ） and Japanese generic ceftriaxone （A ; Sawai, 
B ; Nichi-Iko） products when mixed with Ca2＋ 4.3 mEq/l.  We found that the 
generation rate of IMPs associated with ceftriaxone-calcium salt precipitation among 
the three ceftriaxone products tested was in the order of generic （A）＜original＜
generic （B）, as assessed by light obscuration particle counting.  Typically, after 60 
min, one of the generic ceftriaxone （B）-calcium mixtures was highly opaque with 
numerous aggregates of milky-white precipitates, the original ceftriaxone-calcium 
mixture exhibited noticeable IMPs, and the second generic ceftriaxone （A）-calcium 
mixture was transparent.  The levels of thiotriazinone contaminants, known to be 
a major impurity in ceftriaxone products, were determined by HPLC and found 
to be in the order of generic A＞original＞generic B.  Moreover, the addition of 
a small amount of thiotriazinone into the generic ceftriaxone （B）-calcium mixture 
significantly decreased the amount of IMPs, suggesting that the impurity retards 
ceftriaxone-calcium crystal growth.  We thus concluded that the thiotriazinone 
impurity acts as a suppressive factor of ceftriaxone-calcium salt precipitation, and 
that the high level of thiotriazinone impurity in the ceftriaxone （B） product could 
underlie its lowest rate of IMP generation when mixed with calcium.  We thus 
recommend caution regarding the clinical risk of ceftriaxone-calcium compatibility 
due to impurity contamination in ceftriaxone products.
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Introduction
　Ceftriaxone is a third-generation cephalosporin antibiotic that was introduced worldwide in the 
early 1980s.  It is commercially available as a highly soluble sodium salt ; however, it can form 
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a poorly soluble ceftriaxone-calcium salt when combined with calcium ions.  Thus, in September 
2007, the FDA issued an initial alert to healthcare professionals suggesting that ceftriaxone and 
calcium-containing products should not be coadministered to any patients within 48 hr in order 
to prevent possible end-organ damage secondary to ceftriaxone-calcium precipitation 1）.  In April 
2009, the FDA modified this warning to recommend that ceftriaxone and calcium-containing 
products may be sequentially administered in patients older than 28 days if the infusion lines are 
thoroughly ushed between infusions with a compatible uid 2）.
　The experimental evidence for ceftriaxone-calcium interactions, which became the basis of 
FDA’s alert and subsequent recommendations, was obtained using the original marketed ceftri-
axone sodium preparation, RocephinⓇ 3）.  Recently, Tange et al 4） reported some differences in 
the appearance of IMPs between the original ceftriaxone product and some of the subsequent 
generic versions when 2％ calcium chloride injection solution was added to the product.  How-
ever, the mechanism underlying the above differences in IMP generation remains to be claried.
　To further investigate such ndings 4）, in this study we compared the generation of insoluble 
microparticles （IMPs） over 24 hours among the original ceftriaxone product and two Japanese 
generic versions, i.e., RocephinⓇ （Roche） and ceftriaxone for injection （A ; Sawai and B ; Nichi-
Iko）.  To quantitate the IMPs by size and number of particles, we used a light obscuration 
particle counter and visual observation.  Furthermore, Lambert and Conway 5） compared the 
pharmaceutical qualities of 34 ceftriaxone generic products with RocephinⓇ, and found that the 
most common differences among ceftriaxone products were clarity of solution and contamination 
of thiotriazinone （Ro 11-8390）, which is used in the synthesis of ceftriaxone and remains in 
the manufactured powder as an impurity.  Therefore, we also focused on the different quantities 
of contaminating thiotriazinone among the ceftriaxone products tested in this study, aiming to 
provide a mechanistic insight into the generation of IMPs in ceftriaxone-calcium mixtures.
Materials and methods
Chemicals
　Original （RocephinⓇ） and generic formulations of ceftriaxone sodium （1 g） for injection 
were obtained from Chugai （Tokyo, Japan, as a Roche Group）, Sawai Pharmaceutical Co., Ltd. 
（Osaka, Japan）, and Nichi-Iko Pharmaceutical Co., Ltd. （Toyama, Japan）. Isotonic sodium chlo-
ride solution （100 ml） and calcium chloride injection solution （2％） were purchased from Otsuka 
Pharmaceutical Co., Ltd. （Tokushima, Japan） and tetrahydro-2-methyl-3-thioxo-1,2,4-triazine-
5,6-dione （Ro11-8390）, hereafter referred to as thiotriazinone, was purchased from Fluorochem 
Ltd. （Derbyshire, UK）. 
IMP quantitation by light obscuration particle counting and visual observation
　The size and number of IMPs were determined using a light obscuration particle counter, 
KL-04 （RION Co., Ltd., Tokyo, Japan）.  The volume of each sample was 4.5 ml, and the mean 
value of triplicate samples was calculated.  Visual observational status （VOS） corresponded to 
the following : （-） transparent solution without any IMPs ; （＋） transparent solution with notice-
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able IMPs ; （＋＋） moderately opaque, milky white solution with more abundant IMPs ; and （＋
＋＋） highly opaque, milky white solution with numerous aggregates of IMPs. All VOS data 
were collected and evaluated by three examiners. 
Time courses of IMP generation in the original and generic ceftriaxone solutions mixed with CaCl2
　We added 1.2 ml of 2％ （w/v） calcium chloride solution to 100 ml of the original and generic 
ceftriaxone solutions for injection, to obtain ceftriaxone solutions （10 mg/ml） with the final 
calcium ion concentrations of 4.3 mEq/l.  The size and number of IMPs generated in these 
ceftriaxone-calcium mixtures were measured after the addition of CaCl2, using a light obscuration 
particle counter.
Microscopic assessment
　We added 60 µl of 2％（w/v） calcium chloride solution to 5 ml of the original and generic 
ceftriaxone （B） solutions （10 mg/ml）, resulting in a nal calcium ion concentration of 4.3 mEq/l. 
In another experiment, 4 mg of thiotriazinone （i.e., impurity） was added to the generic ceftriax-
one solutions （10 mg/ml）, to which 60 µl of 2％ （w/v） calcium chloride solution was added, in 
order to investigate the effect of impurity contamination on IMP generation.  Crystallization of 
insoluble ceftriaxone-calcium salt in the ceftriaxone solutions was monitored at 0, 20, and 30 min 
after the addition of CaCl2, using an Olympus IX71 inverted light microscope （Olympus Co., 
Ltd., Tokyo, Japan） connected to a computer （Fujitsu Tokyo, Japan）.
Inuence of thiotriazinone impurity on the generation of IMP in the generic ceftriaxone （B） solu-
tions mixed with CaCl2
　We mixed 4 mg of thiotriazinone, as a simulated impurity, with generic ceftriaxone powder （B） 
（10 mg/ml）, and then dissolved the mixture in 100 ml isotonic sodium chloride solution.  Then, 
1.2 ml of 2％ （w/v） calcium chloride solution was added to obtain a nal calcium ion concentra-
tion of 4.3 mEq/l.  The size and number of IMPs were measured as described above. 
High-performance liquid chromatographic separation of thiotriazinone impurities in the original and 
generic ceftriaxone preparations 
　The contaminating components derived from thiotriazinone impurities in the original and 
generic ceftriaxone products were analyzed by high-performance liquid chromatography （HPLC）, 
according to a method described in the 16 th edition of the Japanese Pharmacopeia （2011）.  The 
HPLC system （Nexera XR, Shimadzu, Kyoto, Japan） used was equipped with an ultraviolet 
detector （SPD-20A）, an integrator, a dual pump （LC-20AT）, and a reverse-phase column 
（TSKgel ODS-80Ts, 5 mm, 4.6 mm × 15 cm） kept at 25℃.  The ow rate was 1.0 ml/min, and the 
wavelength was set at 254 nm. 
Statistical analysis
　The IMP variables are expressed as mean ± S.D. values （n＝ 3）.  The data were compared 
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among the two groups by an unpaired Student’s t-test or among the three products by a one-
way analysis of variance （ANOVA） test followed by the post-hoc Dunnett’s test, using the sta-
tistical software JMPⓇ Pro 11 （SAS Institute Inc., Cary, NC, USA）.  Differences were considered 
to be signicant at P ＜ 0.05.
Results
　The size and number of IMPs generated in the original and generic ceftriaxone （A） solutions 
with Ca2＋ added to a concentration of 4.3 mEq/l were measured by a light obscuration particle 
counter at 15 min, 60 min, and 24 hr after Ca2＋ addition （Table 1）.  There were signicantly 
fewer total IMPs in the generic ceftriaxone （A） solution at 60 min and 24 hr compared to the 
original ceftriaxone solution, indicating a faster rate of ceftriaxone-calcium precipitation in the 
original mixture than in the generic （A） solution.
　Similar analyses were performed to compare IMP generation in the original and generic （B） 
ceftriaxone solutions containing 4.3 mEq/l Ca2＋, in this case with and without 4 mg thiotriazinone 
（impurity）, at 15, 30, and 60 min after Ca2＋ addition （Table 2）.  There was a signicantly higher 
number of total IMPs detected in the generic ceftriaxone （B） solution than in the original 
mixture at 15 and 30 min after the addition of CaCl2＋, although at 24 hr after Ca2＋ addition, 
the number of IMPs in the generic ceftriaxone （B）-calcium mixture was beyond the upper 
Table 1.　 Number of insoluble microparticles （IMPs） and visual observation status （VOS） in 
the original and generic ceftriaxone preparations in the presence of 4.3 mEq/l Ca2＋
Time
Particle size 
（µm）
RocephinⓇ Ceftriaxone （A）
Number of IMPs 
per ml
VOS
Number of IMPs 
per ml
VOS
15 min
2.0-10.0 551.1±61.5
（-）
396±79.6
（-）
10.0-25.0 15.1±4.6 5.6±1.7
25.0-50.0 1.4±1.2 0.1±0.2
Above 50.0 0.1±0.1 0.1±0.1
Total Number 567.7±67.3 401.8±81.5
60 min
2.0-10.0 865.8±156.5
（＋）
399.3±77.8
（-）
10.0-25.0 78.9±49.6 5.3±2.5
25.0-50.0 7.3±3.6 0.0±0.1
Above 50.0 1.6±0.9 0.0±0.0
Total Number 953.6±210.5 404.6±80.3＊
24 hr
2.0-10.0 4505.4±673.3
（＋＋）
3084.6±611.8
（＋＋）
10.0-25.0 7176.1±902.1 512.8±244.4
25.0-50.0 3419.0±863.4 145.3±103.2
Above 50.0 4754.7±1515.5 168.9±191.3
Total Number 19855.2±3954.3 3911.6±1150.8＊
＊ Signicantly different （P＜ 0.05） from the original ceftriaxone product （RocephinⓇ）.
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detection limit.  Therefore, the generic （B） mixture showed faster ceftriaxone-calcium precipita-
tion than the original ceftriaxone–calcium mixture. Moreover, the generic ceftriaxone （B） samples 
with thiotriazinone impurity （4 mg） added showed signicantly decreased numbers of larger-sized 
IMPs when mixed with calcium chloride than the comparable samples without the thiotriazinone 
addition.
　Three independent examiners determined the VOS scores of the ceftriaxone-calcium mixtures, 
and the averaged scores are listed in Tables 1 and 2.  These VOS scores were highly variable 
among the three ceftriaxone products examined, reecting differences in the number of larger 
IMPs （＞ 50 µm in diameter）.  Typically, after 60 min, the generic ceftriaxone （B）-calcium mix-
ture was highly opaque with numerous aggregates of milky-white precipitates, while the original 
ceftriaxone-calcium mixture exhibited noticeable IMP generation, and the other generic ceftriax-
one （A）-calcium mixture was transparent. 
　Fig. 1 shows the morphology of ceftriaxone crystals examined under an inverted light micro-
scope for the original and generic ceftriaxone （B） solutions following the calcium chloride 
additions. Importantly, the generated crystals are easily differentiated morphologically from air 
Table 2.　 Influence of thiotriazinone （impurity） on the generation of insoluble microparticles 
（IMPs） and visual observation status （VOS） in the generic ceftriaxone （B） product 
mixed with 4.3 mEq/l Ca2＋
Time
Particle size
（µm）
Ceftriaxone （B） Ceftriaxone （B）＋ impurity 4 mg
Number of IMPs
per ml
VOS
Number of IMPs
per ml
VOS
15 min
2.0-10.0 2264.8±411.9
（＋＋）
729.7±126.5
（＋）
10.0-25.0 3392.3±1086.5 143.6±4.8
25.0-50.0 2027.4±898.7 28.7±4.5
Above 50.0 3237.1±1523.8 16.1±3.7
Total Number 10921.6±3920.9＊ 918.2±139.4#
30 min
2.0-10.0 2451.5±1209.1
（＋＋）
6414.7±253.5
（＋＋）
10.0-25.0 4461.1±1739.8 2497.1±70.6
25.0-50.0 2558.2±157.0 445.6±17.0
Above 50.0 6956.9±1633.1 426.6±65.2
Total Number 16427.8±4739.0＊ 9783.9±406.3#
60 min
2.0-10.0
† （＋＋＋）
7673.2±1102.0
（＋＋）
10.0-25.0 7079.3±577.9
25.0-50.0 2151.4±73.3
Above 50.0 2182.1±439.1
Total Number 19085.9±2192.2
＊ Significantly different （P ＜ 0.05） from the original ceftriaxone product （RocephinⓇ） listed in 
Table 1.
#  Significantly different （P＜ 0.05） from the control （without an impurity）.
† Not measured （counter overflowed） due to excess number of IMPs.
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bubbles or small dust particles.  Ceftriaxone （B） crystals started to appear at about 20 min after 
the calcium addition, becoming larger with time as numerous crystals aggregated to various sizes 
＞ 100 µm.  The growth rate of crystals turned out to be much higher in the generic ceftriaxone 
（B） solution than in the original ceftriaxone solution at approximately 30 min after the calcium 
addition, supporting the comparison of IMP numbers between the two solutions.  The growth 
of ceftriaxone aggregated crystals was markedly delayed in the generic ceftriaxone （B） mixture 
with 4 mg of thiotriazinone added compared to the sample without such impurities added. 
Contaminating amounts of the thiotriazinone impurity in a 1 g ceftriaxone vial were determined 
by HPLC as 1.35 ± 0.07 mg, 2.92 ± 0.19 mg, and 1.15 ± 0.13 mg （n＝ 3） for the original, generic 
（A）, and generic （B） ceftriaxone products, respectively, giving an impurity scale of generic B ＜ 
original ＜ generic A.  The contaminating amount of thiotriazinone in the original ceftriaxone 
product （i.e., 0.135 （w/w）％ of ceftriaxone in a 1 g vial） is comparable to a previous report 7）.
Fig. 1.　Microscopic assessment of the size and morphology of ceftriaxone-calcium 
salt crystallization in the original and generic ceftriaxone （B） solutions 
（10 mg/ml） mixed with 4.3 mEq/l Ca2＋ （left two lines of panels） and in 
the generic ceftriaxone （B） solution （10 mg/ml） mixed with 4.3 mEq/l Ca2＋ 
and 4 mg thiotriazinone as an impurity （right line of panels）. 
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Discussion
　The present study conrms a previous report of differences in ceftriaxone-calcium salt precipi-
tation between the original ceftriaxone （RocephinⓇ） and subsequent generic products 4）.  Our 
further morphological observation of ceftriaxone crystallization under a light inverted microscope 
（Fig. 1） suggested that the increased IMPs of a larger-size range represented the massive aggre-
gation of ceftriaxone-calcium salt crystals. 
　Our experiments clearly indicated that IMP generation proceeded over time in all the ceftriax-
one products examined.  IMPs ＞ 50 µm were rst detected at 60 min after the calcium addition 
for the original product, at 24 hr for the generic ceftriaxone （A） product, and at 15 min for 
the generic ceftriaxone （B） product. Such differences were clearly reected in the morphologi-
cal assessments of solutions and in the VOS scores.  Interestingly, the generic ceftriaxone （A） 
mixed with 4.3 mEq/l Ca2＋ did not exhibit IMPs ＞ 50 µm at 6 hr after Ca2＋ addition （data not 
shown）.  However, smaller IMPs （＜ 25 µm） were detected in the three ceftriaxone solutions at 
all time points examined, indicating that small cores of ceftriaxone-calcium salt were being gener-
ated, but not aggregating to a visual size.  The i.v. infusion of particulate matter larger than the 
internal diameter （i.d.） of small blood vessels （e.g., capillaries, i.d. 4-9 µm ; arterioles, i.d. approxi-
mately 20 µm） increases the clinical risk of an embolic syndrome 6）.  Therefore, the original and 
two Japanese generic ceftriaxone products examined here are thought to have certain clinical 
risks, despite the lack of visual signs of ceftriaxone-calcium salt precipitation.  In this respect, the 
FDA’s alerts to healthcare professionals suggesting the avoidance of ceftriaxone/calcium coad-
ministration is reasonable.  Indeed, the molar concentration of ceftriaxone used for IMP particle 
counting was 15.1 mM, and that of calcium was 2.15 mM, which correspond to one of the mixing 
processes used clinically （i.e., ceftriaxone and calcium concentrations possible in the Y-site injec-
tion）.
　Overall, the IMP generation rates associated with ceftriaxone-calcium salt precipitation among 
the ceftriaxone products tested in this study were in the order of generic （A） ＜ original ＜ 
generic （B）.  Moreover, we found that the contaminating amounts of thiotriazinone （impurity） 
were in the order of generic （B） ＜ original ＜ generic （A）, which inversely corresponds to the 
rate of IMP generation in these products mixed with CaCl2.  Despite these orders, the actual 
differences in impurity content between the original and the generic （B） products were small. 
Of special note from this study is that only a very small amount of thiotriazinone powder added 
into the generic ceftriaxone （B） product signicantly decreased both the number of IMPs, espe-
cially those of larger size, and the visual score of precipitation associated with ceftriaxone-calcium 
salt. This indicates that low levels of impurity contamination do not cause signicant adverse 
effects in the generic （B） product, based on the growth of ceftriaxone-calcium salt crystals.  The 
data also suggest that a higher number of smaller sized IMPs （2.0-10.0 µm） after 30 min in the 
impurity-added solution could indicate that the generation of ceftriaxone-calcium salt crystals was 
suspended at smaller cores and further growth was retarded by addition of the impurity.  Gener-
ally, an impurity can retard the crystal growth of a major chemical moiety by repeatedly acting 
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on certain crystallographic faces 8）.  Such an impurity may attach briey to the growing crystal 
lattice, but soon de-attach as a compound with a more suitable geometry comes in to take its 
place 9）.  Indeed, the present experiments suggested that thiotriazinone, which is used in the 
ceftriaxone synthesis and remains as a major impurity, acts to suppress the ceftriaxone-calcium 
salt precipitation, albeit in the allowable range of impurity, i.e., 1％ （w/w） of the active moiety 
as dened by the regulatory agency 10）.  Furthermore, the higher contamination of thiotriazinone 
（impurity） in the generic （A） ceftriaxone product might underlie the fact that it had the low-
est rate of IMP generation among the three ceftriaxone products examined when mixed with 
calcium-containing solution. 
　Taken altogether, we have provided a mechanistic insight into observed differences in IMP 
generation among three manufactured products of ceftriaxone sodium when mixed with calcium 
ions, clarifying earlier ndings of similar differences 4）.  Based on the present ndings, we recom-
mend that the clinical risk of ceftriaxone-calcium compatibility be considered with caution regard-
ing thiotriazinone （impurity） contamination in ceftriaxone products. 
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